GLP-1 and GIP/GLP-1 Agonists Show Promise Beyond Diabetes and Obesity

Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and dual Glucose-dependent Insulinotropic Polypeptide (GIP)/GLP-1RAs are established treatments for type 2 diabetes and obesity, primarily by regulating blood sugar and promoting satiety. However, a growing body of research suggests these powerful compounds may have therapeutic benefits for a much wider range of conditions. This review aims to synthesize the current evidence for emerging and off-label applications of GLP-1RAs and dual GIP/GLP-1RAs beyond their approved indications.

The review identified compelling evidence for GLP-1RAs in several emerging areas. In non-alcoholic fatty liver disease (NAFLD), studies consistently showed a 30-50% reduction in liver fat content and 20-40% improvement in fibrosis markers. For polycystic ovary syndrome (PCOS), GLP-1RAs were associated with a 15-25% decrease in androgen levels and improved menstrual regularity in over 60% of patients. Furthermore, preliminary data suggested neuroprotective effects in Alzheimer's disease, with some trials indicating a 10-15% slower cognitive decline over 12-24 months compared to placebo. Dual GIP/GLP-1RAs demonstrated superior efficacy in weight management for individuals with metabolic dysfunction but not primary obesity, achieving an average 15-20% total body weight loss in Phase II trials, surpassing GLP-1RAs alone by 5-10%. The most compelling finding was the consistent evidence for GLP-1RAs significantly improving cardiovascular outcomes beyond weight loss, showing a 20-30% reduction in major adverse cardiovascular events (MACE) in high-risk populations, independent of their primary indications.